These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31611534)

  • 1. Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases.
    Kubo K; Kimura N; Matsuda S; Tsuda M; Mabe K; Kato M
    Intern Med; 2020 Feb; 59(4):507-511. PubMed ID: 31611534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan-Associated Gastric Mucosal Redness in Non-
    Kubo K; Kimura N; Watanabe R; Higashino M; Tsuda M; Kato M
    Case Rep Gastroenterol; 2021; 15(2):751-758. PubMed ID: 34594176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parietal Cell Protrusions and Dilated Oxyntic Glands from Use of Vonoprazan.
    Miyamoto S; Matsuno Y; Kato M; Kudo T; Ono S; Shimizu Y; Sakamoto N
    Am J Gastroenterol; 2017 Dec; 112(12):1899-1901. PubMed ID: 29215611
    [No Abstract]   [Full Text] [Related]  

  • 4. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S; Nishikawa J; Sakaida I
    Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Use of Vonoprazan: A Competitive Acid Blocker.
    Graham DY; Dore MP
    Gastroenterology; 2018 Feb; 154(3):462-466. PubMed ID: 29337157
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis.
    Kang H; Kim BJ; Choi G; Kim JG
    Medicine (Baltimore); 2018 Sep; 97(39):e12574. PubMed ID: 30278564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vonoprazan: a novel potassium-competitive acid blocker].
    Sugano K
    Nihon Rinsho; 2015 Jul; 73(7):1163-8. PubMed ID: 26165074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
    Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
    Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
    Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
    Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
    Hamada K; Uedo N; Tonai Y; Arao M; Suzuki S; Iwatsubo T; Kato M; Shichijo S; Yamasaki Y; Matsuura N; Nakahira H; Kanesaka T; Yamamoto S; Akasaka T; Hanaoka N; Takeuchi Y; Higashino K; Ishihara R; Okada H; Iishi H; Fukui K; Shimokawa T
    J Gastroenterol; 2019 Feb; 54(2):122-130. PubMed ID: 29943163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.